FDA adds two Roche stud­ies to its grow­ing list of par­tial clin­i­cal holds in wake of Keytru­da deaths

Alarmed that an im­bal­ance in deaths among pa­tients tak­ing a com­bi­na­tion of Keytru­da with Cel­gene’s Po­m­a­lyst and Revlim­id could rep­re­sent a threat in that whole class of check­point com­bos, the FDA has added two Tecen­triq stud­ies to its grow­ing list of clin­i­cal tri­als placed on par­tial hold.

Now Roche’s Phase Ib and a Phase Ib/II in re­lapsed/re­frac­to­ry mul­ti­ple myelo­ma and re­lapsed/re­frac­to­ry fol­lic­u­lar lym­phoma will stop en­rolling new pa­tients, though the vol­un­teers who have al­ready signed up can con­tin­ue.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER